Ceftriaxone

• 73384-59-5 ( ceftriaxone )
• 104376-79-6 ( disodium ceftriaxone hemiheptahydrate )

J01DD04

White to light yellow powder ( disodium ceftriaxone hemiheptahydrate )

β -lactam antibiotics

Inhibition of cell wall synthesis

> 155 ° C ( decomposition) ( disodium ceftriaxone hemiheptahydrate )

Risk

2200 mg · kg -1 ( LD50, Mouse, oral, disodium salt)

Template: Infobox chemical / molecular formula search available

Ceftriaxone is an antibiotic from the group of cephalosporins 3rd generation. The bactericidal effect is, as with other β -lactam antibiotics by inhibiting bacterial cell wall synthesis. Ceftriaxone was introduced in 1982 by Hoffmann -La Roche.

Spectrum of activity

Compared to the 1st and 2nd generation cephalosporins, the activity spectrum against gram negative area is easily expanded slightly in the gram-positive. Typical of the cephalosporins Enterokokkenlücke is present in ceftriaxone, and Listeria, Legionella and Pseudomonas aeruginosa are not recognized.

Pharmacokinetics

Since ceftriaxone is not absorbed after oral administration, parenteral administration takes place. Because of the high plasma protein binding of the half-life of 7-8 hours ceftriaxone. It is excreted by the kidneys. Ceftriaxone has a very good tissue penetration and achieved in the CSF therapeutically effective concentrations.

Indications

Ceftriaxone is suitable for the calculated initial therapy of severe, life-threatening infections, including purulent meningitis. However, spectrum gaps must be closed by combination with other antibiotics. Furthermore, ceftriaxone is suitable for the treatment of neuroborreliosis and the time treatment of gonorrhea.

Contraindications

Ceftriaxone is contraindicated in allergy to cephalosporins. Even with penicillin allergy caution because of possible cross allergy. Premature and newborn infants should be administered no ceftriaxone because of the risk of bilirubin encephalopathy ( An alternative cephalosporin 3rd generation would be, for example, cefotaxime ).

Interactions

Ceftriaxone infusions may not be co-administered with calcium containing solutions and drugs not separate cannulas. In addition, calcium - containing products should not be administered until 48 hours after the last dose of ceftriaxone, otherwise can form dangerous calcium - ceftriaxone precipitates. A combination with the antibiotic chloramphenicol should be avoided because the two drugs mutually reduce their effect.

Trade names

Cefotrix (D, A), Rocephin (D, A, CH), Tercefon (A ), numerous generics (D, A, CH)